|
|
Blood, 1 May 2004, Vol. 103, No. 9, pp. 3511-3515.
Prepublished online as a Blood First Edition Paper on January 15, 2004; DOI 10.1182/blood-2003-07-2254.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
Franziska Jundt,
Kristina Schulze Pröbsting,
Ioannis Anagnostopoulos,
Gwendolin Muehlinghaus,
Manik Chatterjee,
Stephan Mathas,
Ralf C. Bargou,
Rudolf Manz,
Harald Stein, and
Bernd Dörken
From the Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum, University Medicine Berlin, Berlin, Germany; Max Delbrück Center for Molecular Medicine, Berlin, Germany; Institute of Pathology, Charité, Campus Benjamin Franklin, University Medicine Berlin, Berlin, Germany; and Deutsches Rheumaforschungszentrum, Berlin, Germany.
Notch receptors expressed on hematopoietic stem cells interact with their ligands on bone marrow stromal cells and thereby control cell fate decisions and survival. We recently demonstrated that Notch signaling is involved in proliferation and survival of B cell-derived tumor cells of classic Hodgkin disease and described a novel mechanism for the oncogenic capacity of Notch. In this study we investigated whether Notch signaling is involved in the tight interactions between neoplastic plasma cells and their bone marrow microenvironment, which are essential for tumor cell growth in multiple myeloma (MM). Here we demonstrate that Notch receptors and their ligand Jagged1 are highly expressed in cultured and primary MM cells, whereas nonneoplastic counterparts show low to undetectable levels of Notch. Functional data indicate that ligand-induced Notch signaling is a growth factor for MM cells and suggest that these interactions contribute to myelomagenesis in vivo. (Blood. 2004;103:3511-3515)

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Notch signaling: a key to the pathogenesis of multiple myeloma?
- Laurie A. Milner
Blood 2004 103: 3253-3254.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
B. Nervi, P. Ramirez, M. P. Rettig, G. L. Uy, M. S. Holt, J. K. Ritchey, J. L. Prior, D. Piwnica-Worms, G. Bridger, T. J. Ley, et al.
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Blood,
June 11, 2009;
113(24):
6206 - 6214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kohlhof, F. Hampel, R. Hoffmann, H. Burtscher, U. H. Weidle, M. Holzel, D. Eick, U. Zimber-Strobl, and L. J. Strobl
Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells
Blood,
May 28, 2009;
113(22):
5506 - 5515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Xiao, L. Ning, and H. Chen
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors
Mol. Cancer Ther.,
February 1, 2009;
8(2):
350 - 356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.-M. Shin, D. J. Shaffer, H. Wang, D. C. Roopenian, and H. C. Morse III
NOTCH Is Part of the Transcriptional Network Regulating Cell Growth and Survival in Mouse Plasmacytomas
Cancer Res.,
November 15, 2008;
68(22):
9202 - 9211.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Huff and W. Matsui
Multiple Myeloma Cancer Stem Cells
J. Clin. Oncol.,
June 10, 2008;
26(17):
2895 - 2900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. B. Meads, L. A. Hazlehurst, and W. S. Dalton
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Clin. Cancer Res.,
May 1, 2008;
14(9):
2519 - 2526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Nefedova, D. M. Sullivan, S. C. Bolick, W. S. Dalton, and D. I. Gabrilovich
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
Blood,
February 15, 2008;
111(4):
2220 - 2229.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. LeBrun, T. Baetz, C. Foster, P. Farmer, R. Sidhu, H. Guo, K. Harrison, R. Somogyi, L. D. Greller, and H. Feilotter
Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Clin. Cancer Res.,
January 15, 2008;
14(2):
478 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Bolos, J. Grego-Bessa, and J. L. de la Pompa
Notch Signaling in Development and Cancer
Endocr. Rev.,
May 1, 2007;
28(3):
339 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kunnimalaiyaan and H. Chen
Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors
Oncologist,
May 1, 2007;
12(5):
535 - 542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Leong and A. Karsan
Recent insights into the role of Notch signaling in tumorigenesis
Blood,
March 15, 2006;
107(6):
2223 - 2233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Zweidler-McKay, Y. He, L. Xu, C. G. Rodriguez, F. G. Karnell, A. C. Carpenter, J. C. Aster, D. Allman, and W. S. Pear
Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies
Blood,
December 1, 2005;
106(12):
3898 - 3906.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Reedijk, S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, G. Lockwood, and S. E. Egan
High-level Coexpression of JAG1 and NOTCH1 Is Observed in Human Breast Cancer and Is Associated with Poor Overall Survival
Cancer Res.,
September 15, 2005;
65(18):
8530 - 8537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Quesnel
Multiple myeloma: all roads lead to cyclin D
Blood,
July 1, 2005;
106(1):
1 - 2.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Jungbluth, S. Ely, M. DiLiberto, R. Niesvizky, B. Williamson, D. Frosina, Y.-T. Chen, N. Bhardwaj, S. Chen-Kiang, L. J. Old, et al.
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
Blood,
July 1, 2005;
106(1):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Takeuchi, Y. Adachi, and Y. Ohtsuki
Skeletrophin, a Novel Ubiquitin Ligase to the Intracellular Region of Jagged-2, Is Aberrantly Expressed in Multiple Myeloma
Am. J. Pathol.,
June 1, 2005;
166(6):
1817 - 1826.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yin
Chondroitin Synthase 1 Is a Key Molecule in Myeloma Cell-Osteoclast Interactions
J. Biol. Chem.,
April 22, 2005;
280(16):
15666 - 15672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Matsumoto and M. Abe
The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions
IBMS BoneKEy,
February 1, 2005;
2(2):
7 - 10.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Houde, Y. Li, L. Song, K. Barton, Q. Zhang, J. Godwin, S. Nand, A. Toor, S. Alkan, N. V. Smadja, et al.
Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines
Blood,
December 1, 2004;
104(12):
3697 - 3704.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Jundt, O. Acikgoez, R. Preissner, and B. Dorken
Manipulation of the Notch Pathway by {gamma}-Secretase Inhibitors as a Novel Therapeutic Approach in Multiple Myeloma.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
645 - 645.
[Abstract]
|
 |
|
|
|